Antibiotics

It is produced by the strain of Str. tanashiensis. At low concentrations, it causes the stagnation of normal cells, but it can cause the death of transformed cells.

It is produced by the strain of Str. tanashiensis. At low concentrations, it causes the stagnation of normal cells, but it can cause the death of transformed cells.

It is produced by the strain of I Leptosphaeria sp. OUPS-4. In order to understand its cytotoxic effects, someone tested Leukemia lymphocyte P388 in culture with an ED50 of 1.13 μg/mL.

It is produced by the strain of J Leptosphaeria sp. OUPS-4. In order to understand its cytotoxic effects, someone tested Leukemia lymphocyte P388 in culture with an ED50 of 1.25 μg/mL.

It is produced by the strain of Paecilomyces lilacinus A-267. It's a peptide antibiotic. It has a strong anti-pathogenic and non-pathogenic yeast and fungi activity, but also has a medium anti-bacterial effect. It was previously reported that Leucinostatin A and B mixtures inhibited HeLa cells. 0.05 μg/mL of Leucinostatin B for a week (0.25 mg/kg・d) has inhibitory effect on the airy ascites carcinoma entity type, and for ascites type is invalid.

It is produced by the strain of Paecilomyces marquandii. It's a peptide antibiotic. It has anti-gram-positive bacterial and fungal effects. It has in vitro cytotoxic activity against HeLa 850, KB cells and sensitive leukemia cells P388 with ID50 of 1.00 ng/mL.

It is produced by the strain of Paecilomyces marquandii. It's a peptide antibiotic. It has anti-gram-positive bacterial and fungal effects.

It is produced by the strain of Paecilomyces marquandii. It's a peptide antibiotic. It has anti-gram-positive bacterial and fungal effects.

It is produced by the strain of Str. kitasatoensis. It's a macrolide antibiotic. It has strong anti-gram-positive bacterial effect, and also has an effect on spirochetes, rickettsium and Chlamydia. After the C3 position on the lactone ring in the structure is acetylated, the activity in vitro is reduced, but the activity in vivo is enhanced, and the toxicity is also reduced. The antibacterial activity of Leucomycin group A is stronger than group B. It has been used in clinical and the indications are the same as erythromycin.

It is produced by the strain of Str. kitasatoensis. It's a macrolide antibiotic. It has strong anti-gram-positive bacterial effect, and also has an effect on spirochetes, rickettsium and Chlamydia. After the C3 position on the lactone ring in the structure is acetylated, the activity in vitro is reduced, but the activity in vivo is enhanced, and the toxicity is also reduced. The antibacterial activity of Leucomycin group A is stronger than group B. It has been used in clinical and the indications are the same as erythromycin.

It is produced by the strain of Str. hygroscopicus TM-531. It's a polyether antibiotic. It has anti-gram-positive bacteria, plant pathogenic bacteria and some protozoa effects.

It is produced by the strain of Str. limosus. It has anti-gram-positive bacterial effect.

It is produced by the strain of Moeszia lindtneri HKI-0054 Paecilomyces sp. HKI-0055 and HKI-0096. It's a peptide antibiotic. It has anti-gram-positive bacterial effect. It had competitive inhibitory effect on human placental proline endopeptidase with IC50 of 3.5 μmol/L. It inhibits the proline endopeptidase from the Flavobacterium meningoseptiu with IC50 of 25 μmol/L.

It is produced by the strain of Str. aureofaciens Tu117. It has the activity of anti-gram-positive bacterial and no activity against fungi (including yeast).

It is produced by the strain of Str. sp. RS-28. It's a macrolide antibiotic. It is resistant to plant pathogenic fungi and algae.

It is produced by the strain of Str. sp. SN-1061M. It has antibacterial effect, but the antibacterial activity is weak. It has strong inhibition of mycobacteria (MIC is 0.16 μg/mL). It has the function of inhibiting glycopeptide biosynthesis, and can inhibit the glycopeptide biosynthesis of Escherichia coli with IC50 of 0.03 μg/mL.

It is produced by the strain of Str. sp. SN-1061M. It has antibacterial effect, but the antibacterial activity is weak. It has strong inhibition of mycobacteria (MIC is 0.16 μg/mL). It has the function of inhibiting glycopeptide biosynthesis, and can inhibit the glycopeptide biosynthesis of Escherichia coli with IC50 of 0.03 μg/mL.

It is produced by the strain of Str. sp. SN-1061M. It has antibacterial effect, but the antibacterial activity is weak. It has strong inhibition of mycobacteria (MIC is 0.16 μg/mL). It has the function of inhibiting glycopeptide biosynthesis, and can inhibit the glycopeptide biosynthesis of Escherichia coli with IC50 of 0.03 μg/mL.

It is produced by the strain of Str. lividus 2230-N. It's an aminoglycoside antibiotic. It has a broad-spectrum effect against bacteria and mycobacterium, and has no cross-resistance with Streptomyces and penicillium, and has protective effect on mice infected with S. aureus and Pseudomonas aeruginosa.

It is produced by the strain of Str. lividus 2230-N. It's an aminoglycoside antibiotic. It has a broad-spectrum effect against bacteria and mycobacterium, and has no cross-resistance with Streptomyces and penicillium, and has protective effect on mice infected with S. aureus.